Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer

(2018) Jonathan M. Loree et al.   Clinical Colorectal Cancer

Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study

(2017) Aaron Sha et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting

(2016) A. Mamo et al.   Current Oncology

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

(2015) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

(2015) Nuri Faruk Aykan et al.   Turkish Journal of Gastroenterology

CAPOX Associated With Toxicities of Higher Grade but Improved Disease-Free Survival When Compared With FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer

(2014) Jonathan M. Loree et al.   Clinical Colorectal Cancer

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

(2011) C. Twelves et al.   ANNALS OF ONCOLOGY

Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis

(2010) Gaetan Des Guetz et al.   EUROPEAN JOURNAL OF CANCER

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY